PLGA and cancer: a comprehensive patent-based review on the present state of art.

Poly (lactic-co-glycolic acid) (PLGA) is a highly efficient biodegradable polymeric nanoparticle (NP). Owing to its low toxicity, controlled and sustained release qualities, and biocompatibility with tissue and cells, the US FDA has approved its usage in drug delivery systems. The manufacturing and characterization techniques, surface changes, encapsulation of anticancer medicines, active or passive tumor targeting, and various PLGA nanoparticle release methods have been explored in the research arena in the past decade and patents have been filed across the globe.

Nanoparticles in pancreatic cancer therapy: a detailed and elaborated review on patent literature.

Introduction: Nanotechnology may open up new avenues for overcoming the challenges of pancreatic cancer therapy as a broad arsenal of anticancer medicines fail to realize their full therapeutic potential in pancreatic ductal adenocarcinoma due to the formation of multiple resistance mechanisms inside the tumor. Many studies have reported the successful use of various nano formulations in pancreatic cancer therapy.

Areas Covered: This review covers all the major nanotechnology-based patent litrature available on renowned patent data bases like Patentscope and Espacenet, through the time period of 2007-2022.